logo
Plus   Neg
Share
Email

PDL BioPharma Decides To Pursue Monetization Of Its Assets - Quick Facts

PDL BioPharma, Inc. (PDLI) has decided to pursue a formal process to unlock value by monetizing the company's assets and returning net proceeds to shareholders. The decision followed the the strategic review process that it initiated in September.

PDL will explore a variety of potential transactions, including a sale of the company, divestiture of its assets or businesses, a spin-off transaction, a merger or a combination. The company has decided to halt the execution of its growth strategy, and cease additional strategic investments.

Also, PDL's Board has authorized the repurchase of issued and outstanding shares of the company's common stock and convertible notes up to an aggregate value of $200 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter of fiscal 2021 on Thursday, Conagra Brands, Inc. (CAG) provided only its adjusted earnings and organic net sales growth guidance for the second quarter of fiscal 2021. The company is still not initiating annual outlook, as is usual, as the impact... Playboy Enterprises, Inc. and Mountain Crest Acquisition Corp. (MCAC) announced Thursday the signing of a definitive merger agreement to return Playboy to the public markets. They also signed definitive purchase agreements with institutional and accredited investors for the purchase of $50 million of... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported an increase in net income for the third quarter, reflecting revenue growth on continued strength in its global snacks and food business and improvement in its global beverage business.
Follow RTT